Pharvaris N.V. (PHVS) fair value analysis
Nasdaq · Updated 2026-10-19
PHVS price how computed
Valuation status
Reports in EURPHVS reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for PHVS until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $31.01
- Sector
- Healthcare
- 12-month range
- $21.59–$38.86
- Market cap
- $2.18B
- From 52-week high
- -20.2%
- Shares outstanding
- 70.2M
- Rank in Healthcare by quality score
- #261 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases, particularly those affecting the respiratory and other systems. The company is based in Switzerland and operates as a Nasdaq-listed entity serving patients in multiple markets globally.
PHVS currently ranks #261 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $2.18B
- EPS (TTM)
- EUR -2.83
- Debt / equity
- 0.00
- Shares outstanding
- 70.2M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 9 · oversold
- 50-day average
- $34.41
- 200-day average
- $30.70
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▼ miss (-9.5%)
2026-03 ▼ miss (-14.5%)
2025-12 ▼ miss (-15.4%)
2025-09 ▲ beat (+10.4%)
2025-06 ▼ miss (-7.8%)
2025-03 ▼ miss (-2.4%)
2024-12 ▲ beat (+11.9%)
2024-09 ▼ miss (-28.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 1 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $57.8
- Target vs last price
- +86.4%
What our data shows for PHVS
- Shares are trading in the middle of their 12-month price range of $21.59–$38.86.
- The 14-day relative strength index sits at an oversold 9.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- PHVS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the PHVS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for PHVS showed a shift in momentum this week, with the RSI zone moving from neutral territory into oversold conditions. The stock's current valuation verdict remains awaiting full valuation, indicating that a comprehensive assessment is still in progress.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PHVS stock undervalued?
PHVS reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for PHVS until same-currency inputs are available.
What is PHVS's TickrTrends verdict?
PHVS is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does PHVS compare to other Healthcare stocks?
PHVS ranks #261 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is PHVS overbought or oversold?
PHVS's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does PHVS report earnings next?
PHVS's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does PHVS usually beat earnings estimates?
Over its last 8 reported quarters PHVS beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PHVS?
Of 14 analysts covering PHVS, 13 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $57.8 (+86.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.